Skip to Main Content

Paper Details

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
Clin Lung Cancer
27
2021
Author NameAffiliation
Simon R CherryUC Davis School of Medicine, UC Davis Medical Center
Primo N LaraUC Davis Medical Center, UC Davis Comprehensive Cancer Center
  • 1 - 2

Datasets

Release 1.2